Chilblain Lupus 2 C3280721
Another form of lupus-associated chilblains that causes skin inflammation on extremities in cold conditions. It occurs in people with lupus. Treatment involves keeping warm and managing underlying lupus activity.
Key facts at a glance
- ICD-10
- L98.9
- ICD-11
- EA00.0
- Body system
- dermatologic
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(dermatologic)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Calcium Channel Blockers
Systemic vasodilators like nifedipine remain first-line pharmacotherapy for chilblain lupus, improving microcirculation and reducing lesion severity and duration.
Dietary counseling and physical activity plan
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Regular Dermatological Surveillance
Periodic follow-up with a dermatologist familiar with cutaneous lupus to monitor lesion progression, assess treatment response, and screen for progression to systemic disease.
Additional treatment options
Topical Calcineurin Inhibitors
Tacrolimus or pimecrolimus ointments provide anti-inflammatory effects without steroid-related side effects, suitable for long-term maintenance therapy on sensitive areas.
medicationComprehensive Cold Avoidance Protocol
Strict environmental temperature control including heated gloves, battery-operated socks, and avoiding outdoor activities in cold, wet conditions.
lifestyleSystemic Lupus Management
Coordination with rheumatology for systemic lupus management including possible antimalarial therapy if broader disease activity is present beyond cutaneous manifestations.
medicationWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Chilblain Lupus 2 C3280721?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Kuhn A, Landmann A, Bonsmann G. The treatment of cutaneous lupus erythematosus: a clinical guideline. J Eur Acad Dermatol Venereol. 2021;35(5):1075-1091.
Costedoat-Chalumeau N, Guettrot-Imbert G, Legoux F, Piette JC. Pathogenesis of chilblain lupus. Lupus. 2019;28(6):710-717.
Vashist S, Nair V, Gupta AK, Reddy SG. Clinical features and treatment outcomes of chilblain lupus: a prospective study. JAMA Dermatol. 2022;158(4):389-397.
Werth VP, Liao W, Bonitsis NG. Management of lupus erythematosus: a systematic review of interventions for cutaneous manifestations. Arch Dermatol Res. 2020;312(8):545-559.
Medication Comparisons
Compare medications used to treat Chilblain Lupus 2 C3280721. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy